Raymond James Downgrades Abbott Labs (ABT) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Abbott (ABT) Sees Q4 Sales Growth in Low-Mid Single-Digit Range
October 17, 2012 9:45 AM EDTAbbott Laboratories (NYSE: ABT) said to see fourth-quarter sales growth in the low-to-mid single-digit range. Comments were made on the company's conference call this morning following... More
Abbott Laboratories (ABT) Tops Q3 EPS by 2c; Narrows FY12 EPS Outlook
October 17, 2012 7:45 AM EDTAbbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $9.77 billion versus the consensus estimate of $9.93 billion.
Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.... More
